Regulating drug information in Europe: A pyrrhic victory for pharmaceutical industry critics?

Sociology of Health and Illness

Volumn 35, Issue 5, 2013, Pages 761-777

  Mulinari, Shai ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Corporate bias; Countervailing forces; Drug information; European Union; Pharmaceuticalisation

Indexed keywords

ARTICLE; CONFLICT OF INTEREST; DRUG INDUSTRY; DRUG INFORMATION; EUROPE; HUMAN; LEGAL ASPECT;

CONFLICT OF INTEREST; DRUG INDUSTRY; DRUG INFORMATION SERVICES; EUROPE; HUMANS;

EID: 84879605420     PISSN: 01419889     EISSN: 14679566     Source Type: Journal    
DOI: 10.1111/j.1467-9566.2012.01528.x     Document Type: Article

References (67)

1. Abbott, A. (2011) Novartis to shut brain research facility, Nature, 480, 7376, 161-2.
2. Abraham, J. (1995) Science, Politics and the Pharmaceutical Industry. London and New York: UCL and St Martins Press.
3. Abraham, J. (2002) The pharmaceutical industry as a political player, Lancet, 360, 1498-502.
4. Abraham, J. (2007) From evidence to theory - neo-liberal corporate bias as a framework for understanding UK pharmaceutical regulation, Social Theory and Health, 5, 2, 161-75.
5. Abraham, J. (2008) Sociology of pharmaceuticals development and regulation: a realist empirical research programme, Sociology of Health & Illness, 30, 6, 869-85.
6. Abraham, J. (2009) Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008, Journal of Health Politics, Policy and Law, 34, 6, 931-77.
7. Abraham, J. (2010) Pharmaceuticalization of society in context: theoretical, empirical and health dimensions, Sociology, 44, 4, 603-22.
8. Abraham, J. (2011) Evolving sociological analyses of 'pharmaceuticalisation': a response to Williams, Martin and Gabe, Sociology of Health & Illness, 33, 5, 726-28.
9. Abraham, J. and Davis, G. (2009) Drug evaluation and the permissive principle: continuities and contradictions between standards and practices in antidepressant regulation, Social Studies of Science, 39, 4, 569-98.
10. Abraham, J. and Lewis, G. (2000) Regulating Medicines in Europe: Competition, Expertise and Public Health. London: Routledge.
11. Adamini, S., Marsee, H., Versluis, E. and Light, D. (2009) Policy making on data exclusivity in the European Union: from industrial interests to legal realities, Journal of Health Politics, Policy and Law, 34, 6, 979-1010.
12. Ager, B. (2007) Direct-to-consumer drug information in Europe, The Lancet, 369, 822.
13. British Medical Association (2008) Response to the European Commission Consultation Regarding the Legal Proposal on Information to Patients. London: BMA.
14. Busfield, J. (2010) 'A pill for every ill': explaining the expansion in medicine use, Social Science & Medicine, 70, 6, 934-41.
15. Committee on the Environment, Public Health and Food Safety (ENVI) (2010) Draft report on the proposal for a directive of the European Parliament and of the Council amending, as regards information to the general public on medicinal products subject to medical prescription, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Brussels: ENVI.
16. Conrad, P. (2005) The shifting engines of medicalization, Journal of Health and Social Behavior, 46, 1, 3-14.
17. Conrad, P. and Leiter, V. (2008) From Lydia Pinkham to Queen Levitra: direct-to-consumer advertising and medicalisation, Sociology of Health & Illness, 30, 6, 825-38.
18. Council of the EU (2008) Council conclusions on the communication from the Commission to the European Parliament and the Council concerning the report on current practice with regards to provision of information to patients on medicinal products. Brussels: Council of the EU.
19. Council of the EU (2009a) Presidency Progress Report on the Proposal for Amending Directive 2001/83/Ec. Brussels: Council of the EU.
20. Council of the EU (2009b) Press release: 2947th Council meeting: Employment, Social Policy, Health and Consumer Affairs. Luxembourg: Council of the EU.
21. Davis, C. and Abraham, J. (2011) Rethinking innovation accounting in pharmaceutical regulation: a case study in the deconstruction of therapeutic advance and therapeutic breakthrough, Science Technology & Human Values, 36, 6, 791-815.
22. European Commission (n.da.) Medicinal products for human use, updated 2012. Available from http://ec.europa.eu/health/human-use/information-to-patient/legislative-developments_en.htm (last accessed 9 September 2012).
23. European Commission (n.db) Phamaceutical package. Available at http://ec.europa.eu/health/human-use/package_en.htm (last accessed 10 September 2012).
24. European Commission (2007a) Draft Report on Current Practice with Regard to Provision of Information to Patients on Medicinal Products. Brussels: DG ENTR.
25. European Commission (2007b) Draft report on current practices with regard to provision of information to patients on medicinal products: summary of the Public Consultation. Brussels: DG ENTR.
26. European Commission (2008a) Key ideas of a legal proposal on information to patients. Brussels: DG ENTR.
27. European Commission (2008b) Key ideas of a legal proposal on information to patients: summary of the public consultation responses. Brussels: DG ENTR.
28. European Commission (2008c) Commission staff working document SEC(2008) 2667: impact assessment. Brussels: European Commission.
29. European Commission (2008d) Proposal for a directive of the European Parliament and of the Council amending, as regards information to the general public on medicinal products subject to medical prescription, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Brussels: European Commission.
30. European Federation of Pharmaceutical Industries and Associations (EFPIA) (2008) EFPIA Contribution to the European Commission Public Consultation on a Legal Proposal on Information to Patients. Brussels: EFPIA.
31. European Parliament (n.d.) Medicinal products for human use, updated 2012. http://www.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&reference=2008/0256%28COD%29 (last accessed 10 September 2012).
32. European Parliament (2010a) Debates Monday, 22 November 2010, Strasbourg. Available at http://www.europarl.europa.eu/sides/getDoc.do?type=CRE&reference=20101122&secondRef=ITEM-017&language=EN&ring=A720100290 (last accessed 3 September 2012).
33. European Parliament (2010b) Legislative resolution on the proposal for a directive of the European Parliament and of the Council amending, as regards information to the general public on medicinal products subject to medical prescription, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Brussels: European Parliament.
34. European Parliament and Council (2004) Directive 2004/27/EC, Article 88a. Official Journal of the EU, 136/51.
35. European Voice (2010) Debate report - the right to know? Should information to patients be restricted?European Voice. Available at http://www.europeanvoice.com/article/events/2010/debate-report-the-right-to-know-should-information-to-patients-be-restricted-/67409.aspx (last accessed 3 September 2012).
36. Fjellner, C. (2009a) Läkemedelsinformation till allmänheten. Available at http://www.fjellner.eu/lkemedelsinormation-till-allmnheten (last accessed 3 September 2012).
37. Fjellner, C. (2009b) Fjellners anförande om patientinfromation. Available at http://www.fjellner.eu/fjellners-anforande-om-patientinfromation (last accessed 3 September 2012).
38. Fjellner, C. (2010a) Report on the Proposal for a Directive of the European Parliament and of the Council Amending, As Regards Information to the General Public on Medicinal Products Subject to Medical Prescription, Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. Brussels: ENVI.
39. Fjellner, C. (2010b) Pressmeddelande: EU-lagstiftning för läkemedelsinformation efter svensk förebild. Available at http://www.fjellner.eu/pressmeddelande-eu-lagstiftning-for-lakemedelsinformation-efter-svensk-forebild/ (last 3 September 2012).
40. Fredriksson, R. (2010) FASS kan hotas av EU-regler. SVT.se. Available at http://svt.se/2.22620/1.1935519/fass_kan_hotas_av_eu-regler?lid=senasteNytt_275214 (last accessed 3 September 2012).
41. Gabe, J. and Bury, M. (1996) Halcyon nights: a sociological account of a medical controversy, Sociology, 30, 3, 447-69.
42. Health Action International Europe, ISDB, AIM, BEUC et al. (2007) Relevant Health Information for Empowered Citizens. Brussels: Joint Declaration.
43. Healy, D. (1997) The Antidepressant Era. Cambridge: Harvard University Press.
44. Kirsch, I., Deacon, B.J., Huedo-Medina, T.B., Scoboria, A., et al. (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration, PLoS Med, 5, 2, e45.
45. Krishnan, V. and Nestler, E.J. (2008) The molecular neurobiology of depression, Nature, 455, 7215, 894-902.
46. Light, D. (1995) Countervailing powers. In Johnson, T., Larkin, G. and Saks, M. (eds) Health Professions and the State in Europe. London: Routledge.
47. Medawar, C. (2008) A cynical consultation exercise?BMJ, 336, 7648, 787.
48. Moncrieff, J. (2007) Co-opting psychiatry: the alliance between academic psychiatry and the pharmaceutical industry, Epidemiologia e Psichiatria Sociale, 16, 3, 192-6.
49. Moynihan, R. (2007) Citizens' alliance condemns EC report as 'undocumented' and 'biased', BMJ, 334, 7607, 1290.
50. Mulinari, S. (2012) Monoamine theories of depression: historical impact on biomedical research, Journal of History of the Neurosciences, 21, 4, 366-92.
51. Perman, E. (1990) Voluntary control of drug promotion in Sweden, New England Journal of Medicine, 323, 9, 616-7.
52. Picker Institute Europe (2007) Current Practice with Regard to Provision of Information to Patients on Medicinal Products: a Response from Picker Institute Europe to the Report by the Enterprise and Industry Directorate-General. Brussels: PIE.
53. Ranik, J. (2008) Commission in-fighting delays pharma proposal. European Voice. Available at http://www.europeanvoice.com/article/imported/commission-in-fighting-delays-pharma-proposal/62770.aspx (last accessed 3 September 2012).
54. Shaw, J. (2011) Patient information on prescribed drugs, BMJ, 342.
55. Shorter, E. (2009) Before Prozac: the Troubled History of Mood Disorders in Psychiatry. Oxford: Oxford University Press.
56. Sveriges Läkarförbund (2008). Europeiska kommissionens konsultation: Legal proposal on information to patient. Stockholm: SLF.
57. The Lancet (2007) The direct-to-consumer advertising genie, Lancet, 369, 9555, 1.
58. Swedish Association of the Pharmaceutical Industry (1966) FASS. Stockholm: Läkemedelsinformation.
59. Swedish Association of the Pharmaceutical Industry (1983) Patient-FASS. Stockholm: Läkemedelsinformation.
60. Swedish Association of the Pharmaceutical Industry (2008) FASS - the Swedish Medicines Information Engine. Stockholm: LIF.
61. Van Lierop, T. (2007) Direct-to-consumer drug advertisement in Europe, Lancet, 369, 1790.
62. Verheugen, G. (2006) SPEECH/06/547: Delivering better information, better access and better prices. Brussels: European Commission. Available at http://europa.eu/rapid/pressReleasesAction.do?reference=SPEECH/06/547&format=HTML&aged=1&language=EN&guiLanguage=fr (last accessed 3 September 2012).
63. Watson, R. (2003) EU health ministers reject proposal for limited direct-to-consumer advertising, BMJ, 326, 1284.
64. Watson, R. (2008) Proposal to allow drug companies to give information to public sparks outcry, BMJ, 337, doi: 10.1136/bmj.a3043
65. Watson, R. (2010) Drug companies may provide information directly to EU patients but under strict conditions, BMJ, 341, doi: 10.1136/bmj.c6883.
66. Williams, S.J., Gabe, J. and Davis, P. (2008) The sociology of pharmaceuticals: progress and prospects, Sociology of Health & Illness, 30, 6, 813-24.
67. Williams, S.J., Martin, P. and Gabe, J. (2011) The pharmaceuticalisation of society? A framework for analysis, Sociology of Health & Illness, 33, 5, 710-25.